Absci to Host R&D Day on December 12, 2024
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its upcoming 2024 R&D Day scheduled for December 12th in New York City. The event will run from 9:00 a.m. to approximately 12:00 p.m. Eastern Time, featuring presentations from Absci's leadership team and guest speakers, followed by an interactive Q&A session. Interested participants can access both live and archived webcasts of the event through the company's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI), un'azienda che utilizza l'IA generativa orientata ai dati per la creazione di farmaci, ha annunciato il suo prossimo Giorno di Ricerca e Sviluppo 2024, previsto per il 12 dicembre a New York. L'evento si svolgerà dalle 9:00 alle 12:00 circa, ora orientale, e includerà presentazioni del team dirigenziale di Absci e di relatori ospiti, seguite da una sessione di domande e risposte interattiva. I partecipanti interessati possono accedere sia alle dirette sia alle registrazioni dell'evento attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.absci.com.
Absci (Nasdaq: ABSI), una empresa de creación de medicamentos utilizando IA generativa basada en datos, ha anunciado su próximo Día de I+D 2024 programado para el 12 de diciembre en Nueva York. El evento se llevará a cabo de 9:00 a.m. a aproximadamente 12:00 p.m. hora del Este, con presentaciones del equipo directivo de Absci y oradores invitados, seguidas de una sesión de preguntas y respuestas interactiva. Los participantes interesados pueden acceder a las transmisiones en vivo y grabadas del evento a través del sitio web de relaciones con los inversores de la empresa en investors.absci.com.
Absci (Nasdaq: ABSI)는 데이터 기반의 생성 AI를 활용한 약물 개발 회사로, 2024 연구개발의 날을 12월 12일 뉴욕에서 개최한다고 발표했습니다. 이번 행사는 동부 표준시 기준으로 오전 9시부터 약 오후 12시까지 진행되며, Absci의 경영진과 초청 연사들의 발표가 있을 것이고, 그 뒤에는 인터랙티브 Q&A 세션이 이어집니다. 관심 있는 참가자는 회사의 투자자 관계 웹사이트인 investors.absci.com을 통해 행사에 대한 생중계 및 녹화된 내용을 모두 접속할 수 있습니다.
Absci (Nasdaq: ABSI), une entreprise de création de médicaments utilisant l'IA générative axée sur les données, a annoncé sa prochaine Journée R&D 2024 prévue pour le 12 décembre à New York. L'événement se déroulera de 9h00 à environ 12h00, heure de l'Est, et comprendra des présentations de l'équipe de direction d'Absci et d'intervenants invités, suivies d'une session de questions-réponses interactive. Les participants intéressés peuvent accéder aux webdiffusions en direct et enregistrées de l'événement via le site Web des relations investisseurs de l'entreprise à l'adresse investors.absci.com.
Absci (Nasdaq: ABSI), ein datenorientiertes Unternehmen zur Generierung von KI-gesteuerten Arzneimitteln, hat seinen bevorstehenden Forschungstag 2024 bekannt gegeben, der am 12. Dezember in New York City stattfinden wird. Die Veranstaltung läuft von 9:00 Uhr bis etwa 12:00 Uhr Eastern Time und umfasst Präsentationen des Führungsteams von Absci sowie Gastredner, gefolgt von einer interaktiven Frage- und Antwortsitzung. Interessierte Teilnehmer können sowohl Live- als auch aufgezeichnete Webcasts der Veranstaltung über die Investor-Relations-Website des Unternehmens unter investors.absci.com verfolgen.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City.
The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci’s leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time.
Interested parties may access a live and archived webcast of Absci’s R&D Day on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When is Absci's (ABSI) 2024 R&D Day?
How can investors watch Absci's (ABSI) 2024 R&D Day presentation?
What will be presented at Absci's (ABSI) 2024 R&D Day?
Where is Absci's (ABSI) 2024 R&D Day being held?
